The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The Proteome of Primary Prostate Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Self-citationGlobal quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“Most importantly, our data suggests that gene expression changes have limited value as predictors of proteomic changes in prostate tumors, in line with previous observations in other mammalian systems [9,10].”
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Mass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820
Proteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
Deep proteome and transcriptome mapping of a human cancer cell line
Nagaraj, N., Wisniewski, J. R., Geiger, T., Cox, J., Kircher, M., Kelso, J., Pääbo, S., & Mann, M. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.81 · Cited by 979
Self-citationHelms, J. B., & Rothman, J. E. (1992) · Nature · doi:10.1038/360352a0 · Cited by 746
A dual pressure linear ion trap orbitrap instrument with very high sequencing speed
Olsen, J. V., Schwartz, J. C., Griep-Raming, J., Nielsen, M. L., Damoc, E., Denisov, E., Lange, O., Remes, P., Taylor, D., Splendore, M., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900375-mcp200 · Cited by 464
Self-citationThe Coming Age of Complete, Accurate, and Ubiquitous Proteomes
Mann, M., Kulak, N. A., Nagaraj, N., & Cox, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.029 · Cited by 350
Self-citationExtensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma
Wiśniewski, J. R., Ostasiewicz, P., Duś, K., Zielińska, D. F., Gnad, F., & Mann, M. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.44 · Cited by 248
Self-citation
Research works printed but not linked: 39
- Siegel, 2014, Cancer statistics, 2014, CA Cancer J Clin, 64, 9, 10.3322/caac.21208 · DOI · Paper page
- Rider, 2013, Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study, Eur Urol, 63, 88, 10.1016/j.eururo.2012.08.001 · DOI · Paper page
- Loeb, 2013, Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer, J Urol, 190, 1742, 10.1016/j.juro.2013.05.054 · DOI
- Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat Genet, 44, 685, 10.1038/ng.2279 · DOI · Paper page
- Taylor, 2010, Integrative genomic profiling of human prostate cancer, Cancer Cell, 18, 11, 10.1016/j.ccr.2010.05.026 · DOI · Paper page
- Geiger, 2010, Super-SILAC mix for quantitative proteomics of human tumor tissue, Nat Methods, 7, 383, 10.1038/nmeth.1446 · DOI · Paper page
- Ostasiewicz, 2010, Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry, J Proteome Res, 9, 3688, 10.1021/pr100234w · DOI · Paper page
- Cox, 2011, Andromeda: a peptide search engine integrated into the MaxQuant environment, J Proteome Res, 10, 1794, 10.1021/pr101065j · DOI · Paper page
- Josefsson, 2012, Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance, Scand J Urol Nephrol, 46, 247, 10.3109/00365599.2012.669791 · doi:10.3109/00365599.2012.669791
- Andren, 2006, How well does the Gleason score predict prostate cancer death?. A 20-year followup of a population based cohort in Sweden, J Urol, 175, 1337, 10.1016/S0022-5347(05)00734-2 · DOI · Paper page
- Ahlqvist, 2013, Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer, Oncogene, 32, 1601, 10.1038/onc.2012.175 · DOI
- Whitaker-Menezes, 2011, Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue, Cell Cycle, 10, 4047, 10.4161/cc.10.23.18151 · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Kobayashi, 2011, DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer, Genome Res, 21, 1017, 10.1101/gr.119487.110 · DOI · Paper page
- Lindberg, 2013, The mitochondrial and autosomal mutation landscapes of prostate cancer, Eur Urol, 63, 702, 10.1016/j.eururo.2012.11.053 · DOI
- Costello, 1989, Prostate epithelial cells utilize glucose and aspartate as the carbon sources for net citrate production, Prostate, 15, 335, 10.1002/pros.2990150406 · doi:10.1002/pros.2990150406
- Leiblich, 2006, Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer, Oncogene, 25, 2953, 10.1038/sj.onc.1209262 · DOI
- Egevad, 2002, Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection, J Urol, 168, 509, 10.1016/S0022-5347(05)64669-1 · doi:10.1016/s0022-5347(05)64669-1
- Stark, 2009, Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?, J Clin Oncol, 27, 3459, 10.1200/JCO.2008.20.4669 · DOI · Paper page
- Bostwick, 1998, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases, Cancer, 82, 2256, 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S · DOI · Paper page
- Hagglof, 2012, The stroma-a key regulator in prostate function and malignancy, Cancers (Basel), 4, 531, 10.3390/cancers4020531 · DOI
- Rasiah, 2006, Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis, Cancer Epidemiol Biomarkers Prev, 15, 711, 10.1158/1055-9965.EPI-05-0752 · DOI
- Funkelstein, 2008, Cathepsin L participates in the production of neuropeptide Y in secretory vesicles, demonstrated by protease gene knockout and expression, J Neurochem, 106, 384, 10.1111/j.1471-4159.2008.05408.x · doi:10.1111/j.1471-4159.2008.05408.x
- Massoner, 2013, Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y, PloS One, 8, e55207, 10.1371/journal.pone.0055207 · DOI
- Hagglof, 2014, TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers, PloS One, 9, e86824, 10.1371/journal.pone.0086824 · DOI
- Tan, 2014, Evaluation of ERG responsive proteome in prostate cancer, Prostate, 74, 70, 10.1002/pros.22731 · DOI
- Tomlins, 2007, Integrative molecular concept modeling of prostate cancer progression, Nat Genet, 39, 41, 10.1038/ng1935 · DOI · Paper page
- Chuan, 2010, Ezrin mediates c-Myc actions in prostate cancer cell invasion, Oncogene, 29, 1531, 10.1038/onc.2009.442 · DOI
- Tennakoon, 2014, Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch, Oncogene, 33, 5251, 10.1038/onc.2013.463 · DOI · Paper page
- Rambold, 2011, Mechanisms of mitochondria and autophagy crosstalk, Cell Cycle, 10, 4032, 10.4161/cc.10.23.18384 · DOI · Paper page
- Mao, 1966, Human prostatic carcinoma: an electron microscope study, Cancer Res, 26, 955
- Movsas, 2000, Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study, Cancer, 89, 2018, 10.1002/1097-0142(20001101)89:9<2018::AID-CNCR19>3.0.CO;2-Y · DOI
- Margel, 2013, Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes, J Clin Oncol, 31, 3069, 10.1200/JCO.2012.46.7043 · DOI · Paper page
- Egevad, 2002, Prognostic value of the Gleason score in prostate cancer, BJU Int, 89, 538, 10.1046/j.1464-410X.2002.02669.x · doi:10.1046/j.1464-410x.2002.02669.x
- Ueda, 2013, Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide, J Proteome Res, 12, 4497, 10.1021/pr400547s · doi:10.1021/pr400547s
- Nagakawa, 2001, Effect of prostatic neuropeptides on migration of prostate cancer cell lines, Int J Urol, 8, 65, 10.1046/j.1442-2042.2001.00250.x · DOI
- Ruscica, 2006, Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells, Endocrinology, 147, 1466, 10.1210/en.2005-0925 · doi:10.1210/en.2005-0925
- Allen, 2011, Neuropeptide Y acts within the rat testis to inhibit testosterone secretion, Neuropeptides, 45, 55, 10.1016/j.npep.2010.10.006 · DOI
- Kitlinska, 2005, Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors, Cancer Res, 65, 1719, 10.1158/0008-5472.CAN-04-2192 · DOI
Cited by
The Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Self-citationPerseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research
Tyanova, S., & Cox, J. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7493-1_7 · Cited by 661
Self-citationRecent advances in mass spectrometry based clinical proteomics: applications to cancer research
Macklin, A., Khan, S., & Kislinger, T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09283-w · Cited by 317
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Iglesias-Gato, D., Thysell, E., Tyanova, S., Crnalic, S., Santos, A., Lima, T. S., Geiger, T., Cox, J., Widmark, A., Bergh, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1229 · Cited by 106
Self-citation
Metadata
- Authors
- Iglesias-Gato, D., Wikström, P., Tyanova, S., Lavallee, C., Thysell, E., Carlsson, J., Hägglöf, C., Cox, J., Andrén, O., Stattin, P., Egevad, L., Widmark, A., Bjartell, A., Collins, C. C., Bergh, A., Geiger, T., Mann, M., & Flores-Morales, A.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 69
- Issue
- 5
- Pages
- 942-952
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2183117764
- Cited by
- 163
- References
- 11
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Proteome of Primary Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2015.10.053
- The paper
- Iglesias-Gato, D., Wikström, P., Tyanova, S., Lavallee, C., Thysell, E., Carlsson, J., Hägglöf, C., Cox, J., Andrén, O., Stattin, P., Egevad, L., Widmark, A., Bjartell, A., Collins, C. C., Bergh, A., Geiger, T., Mann, M., & Flores-Morales, A. (2016). The Proteome of Primary Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2015.10.053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.